Tesamorelin vs AOD 9604 compared: FDA approval, how each peptide works, research findings, dosing, and safety profile so you can tell them apart.
Tesamorelin and AOD 9604 are both peptides discussed for fat loss, but they belong to different drug classes and are backed by very different evidence. Tesamorelin is an FDA-approved growth hormone–releasing hormone (GHRH) analog that raises the body's own growth hormone and has reduced visceral fat in randomized human trials. AOD 9604 is a synthetic fragment of human growth hormone that is not FDA-approved for any human use and failed to beat placebo for weight loss in its largest clinical study.
For anyone weighing tesamorelin vs aod 9604, the practical takeaway is straightforward: one peptide has an approved medical indication and published clinical results, and the other does not.
The Short Answer at a Glance
Here is the comparison in plain terms before the details:
- Class: Tesamorelin is a 44-amino acid GHRH analog; AOD 9604 is a 16-amino acid fragment of human growth hormone.
- Approval: Tesamorelin (Egrifta WR) is FDA-approved for HIV-associated lipodystrophy; AOD 9604 is not approved for any human indication.
- Hormone effects: Tesamorelin raises growth hormone and IGF-1; AOD 9604 does not.
- Evidence: Tesamorelin has replicated reductions in visceral fat; AOD 9604 showed no significant weight loss over placebo in Phase IIb testing.
- Access: Tesamorelin requires a prescription; AOD 9604 is typically sold as a research chemical not intended for human use.
What Is Tesamorelin?
Tesamorelin is a synthetic version of growth hormone–releasing hormone, also called GRF 1-44. It binds GHRH receptors in the pituitary gland and prompts the body to release its own growth hormone in pulses, which in turn raises IGF-1 levels.
The FDA approved tesamorelin in 2010 for HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the abdomen. In the trials behind that approval, adults who received daily injections saw roughly a 15% to 18% reduction in visceral adipose tissue over 26 weeks compared with placebo.
Tesamorelin is not approved for general weight loss or cosmetic fat reduction. It is a prescription product with real hormonal effects, and its label includes warnings about increased blood sugar, injection site reactions, joint pain, swelling, and the long-term uncertainty that comes with elevated IGF-1.
What Is AOD 9604?
AOD 9604 is a modified piece of human growth hormone corresponding to amino acids 176–191, with an added tyrosine intended to improve stability. It was developed by an Australian company, Metabolic Pharmaceuticals, as a candidate anti-obesity drug.
Unlike growth hormone itself, AOD 9604 does not bind the growth hormone receptor and has not been shown to raise IGF-1. Researchers proposed that it acts directly on fat cells to stimulate lipolysis, and early laboratory work supported that idea.
AOD 9604 is essentially a stabilized cousin of hgh frag 176-191, so aod 9604 vs hgh frag 176-191 discussions usually come down to the tyrosine modification and half-life rather than a genuinely different mechanism.
Human results did not follow the laboratory promise. In a Phase IIb trial completed in the mid-2000s, AOD 9604 did not produce statistically significant weight loss compared with placebo, and development as an obesity treatment was discontinued. AOD 9604 has never been approved by the FDA or any comparable regulator for human use.
Tesamorelin vs AOD 9604: Side-by-Side Comparison
| Feature | Tesamorelin | AOD 9604 |
|---|---|---|
| Class | GHRH analog, 44 amino acids | hGH fragment 176-191 analog, 16 amino acids |
| FDA status | Approved (Egrifta WR) for HIV-associated lipodystrophy | Not approved for any human use |
| Mechanism | Stimulates pituitary release of growth hormone | No growth hormone receptor binding; proposed direct effect on fat cells |
| IGF-1 effect | Raises IGF-1 | No IGF-1 increase in published studies |
| Key human result | About 15% to 18% less visceral fat at 26 weeks vs placebo | No significant weight loss vs placebo in Phase IIb |
| Typical studied dose | 1 mg or 2 mg injected subcutaneously once daily | Roughly 300 mcg subcutaneously daily in industry protocols |
| Common side effects | Injection site reactions, joint pain, swelling, higher blood sugar | Generally mild in short trials; limited long-term human data |
| Legal access in the US | Prescription only | Sold as a research chemical; not legal for human consumption |
Dosing, Evidence, and Stacking Questions
Dosing as studied
Tesamorelin is prescribed at 1 mg or 2 mg injected subcutaneously once daily, with injection sites rotated to limit irritation. AOD 9604 is often described at about 300 mcg per day in grey-market protocols, but a dose that never produced a confirmed benefit in trials is not a settled standard.
What the evidence actually supports
Tesamorelin's visceral fat reduction has been reproduced in randomized, placebo-controlled trials in people with HIV-associated lipodystrophy. AOD 9604's most rigorous human test was negative for weight loss. That gap in evidence quality matters more than any single anecdotal report.
Stacking and comparison questions
Many people ask about using aod 9604 with tesamorelin, yet no published trial has tested that pairing, and adding an unapproved peptide does not improve the safety profile of a prescription hormone secretagogue.
Similar logic applies across the category. Sermorelin is another GHRH analog, so sermorelin vs aod 9604 comes down to the same divide: upstream growth hormone signaling versus a fragment that does not raise IGF-1. In the same way, an aod 9604 vs hgh comparison overlooks the fact that only growth hormone itself produces the broad IGF-1 elevation responsible for most of its effects.
Anecdotal aod-9604 mots-c tesamorelin stack protocols circulate on forums, but there is no clinical evidence that stacking three peptides improves fat loss or reduces risk.
Safety, Sourcing, and Legal Status
Tesamorelin is available only by prescription in the United States, and treatment generally involves monitoring IGF-1 and blood sugar. It is not appropriate for people with active cancer, and long-term safety data beyond a few years is limited.
AOD 9604 sold online is not regulated for purity, sterility, or identity. Products labeled for research use only are not manufactured to pharmaceutical standards, and injecting them carries risks that include contamination and dosing errors.
AOD 9604 has been reported as generally well tolerated in short trials, but that does not make an unapproved, unregulated injectable safe for routine use at home.
Anyone considering either peptide should talk with a licensed healthcare professional, especially if they have diabetes, a history of cancer, or take medications that affect blood sugar.
The Bottom Line
The two compounds are frequently grouped together online, but the differences are substantial:
- Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has randomized trial data showing visceral fat reduction.
- AOD 9604 is not FDA-approved for human use and failed to outperform placebo for weight loss.
- Tesamorelin and AOD 9604 are not interchangeable, because one raises growth hormone and IGF-1 and the other does not.
- Neither peptide substitutes for medical care, and unregulated research chemicals carry unknown risks.
Frequently Asked Questions
Is tesamorelin or AOD 9604 better for fat loss?
Tesamorelin has the stronger evidence base. It is FDA-approved for HIV-associated lipodystrophy and reduced visceral fat by roughly 15% to 18% versus placebo in randomized trials. AOD 9604 failed to show significant weight loss over placebo in its main Phase IIb obesity study, and neither peptide is approved for general weight loss.
Is AOD 9604 FDA-approved?
No. AOD 9604 has never been approved by the FDA or any comparable regulator for human use. It was studied as an obesity drug in the 2000s, did not meet its weight-loss endpoints, and is now sold in the US only as a research chemical that is not intended for human consumption.
Can you take tesamorelin and AOD 9604 together?
There is no published human trial testing tesamorelin and AOD 9604 together, so the combination has no established benefit or safety profile. Stacking peptides also multiplies cost and injection burden without clinical evidence to justify it. Talk with a licensed healthcare professional before combining any injectable compounds.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.